Skip to content
DataLookout
Start free
Menu

NCT07915245

A Study of LY4247147 in Participants With Obesity or Overweight Who Are Otherwise Healthy

StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Part A and C: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Timeframe: Baseline through End of the Follow-up (Estimated as Week 25)
Part B: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Timeframe: Baseline through End of the Follow-up (Estimated as Week 33)

Secondary (6)

Part A and C: Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY4247147
Part B: PK: Cmax of LY4247147
Part A: PK: Time of Maximum Observed Drug Concentration (Tmax) of LY4247147
Part B: PK: Tmax of LY4247147
Part A and C: PK: Area Under the Concentration Versus Time Curve (AUC) of LY4247147
Show 1 moreShow less
Part B: PK: AUC of LY4247147

Arms and interventions

LY4247147 Part AExperimental

LY4247147 administered subcutaneously (SC)

Placebo Part APlacebo comparator

Placebo administered SC

LY4247147 Part BExperimental

LY4247147 administered SC

Placebo Part BPlacebo comparator

Placebo administered SC

LY4247147 Part CExperimental

LY4247147 administered intravenously (IV)

Drugs: LY4247147, Placebo

Sites

3 sites in 2 countries

United States 2, Singapore 1